Melissa Middeldorp
banner
melissamidd.bsky.social
Melissa Middeldorp
@melissamidd.bsky.social
Postdoctoral Cardiac Researcher | Lifestyle & risk factor management in AF | Allied Health | University of Adelaide | University Medical Center Groningen | Harvard SPH
Reposted by Melissa Middeldorp
NEW! Tune into episode 82 of The Lead!

🎙️ Host: Jason T. Jacobson, MD, FHRS
🎤 Guests: T. Jared Bunch, MD, FHRS and Dominik K Linz, MD, PhD

Listen on your preferred podcast platform ➡️ bit.ly/40Z6tBh

#EPeeps #medpod #podcast #PodcastAndChill #HRS365 #ConductionSystemPacing #BiventricularPacing
November 22, 2024 at 2:40 PM
Reposted by Melissa Middeldorp
Congrats to Rajeev Pathak, @prashsanders.bsky.social and team on the ARREST-AF RCT.

Incredibly informative data - adjective comprehensive risk factor optimisation significantly improved post ablation AF freedom.

We now have RCT evidence supporting RFM as a foundation and pillar of AF management.
November 18, 2024 at 8:09 PM
Reposted by Melissa Middeldorp
Fantastic presentation from Mina Chung on the results of the TRIM-AF study.

RFM +/- Metformin had benefit in symptoms but no benefit on AF burden.
November 18, 2024 at 4:35 PM
Reposted by Melissa Middeldorp
It's almost time for #AHA24!
November 14, 2024 at 10:41 PM
Reposted by Melissa Middeldorp
#Tirzepatide for Obesity Treatment & Diabetes Prevention
SURMOUNT-1 Trial

✅ Reduced progression to T2DM by 93%
#CardioSky #EndoSky #MedSky #NEJM
www.nejm.org/doi/full/10....
Tirzepatide for Obesity Treatment and Diabetes Prevention | NEJM
Obesity is chronic disease and causal precursor to myriad other conditions, including type 2 diabetes. In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was shown to provide substantial a...
www.nejm.org
November 14, 2024 at 3:44 AM
Reposted by Melissa Middeldorp
We will be presenting ARREST-AF as a late breaking clinical trial at #AHA24

Impact of #LRFM on AF ablation outcomes

Look forward to seeing everyone in Chicago
November 11, 2024 at 8:39 PM